BioScrip Announces Availability of ALS Home Infusion Therapy
October 05 2017 - 8:00AM
BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the
largest independent national provider of infusion and home care
management solutions, is pleased to announce that it can now
dispense and administer Radicava® (edaravone), the first treatment
option for amyotrophic lateral sclerosis (ALS) approved
by the U.S. Food and Drug Administration (FDA) in more than 20
years. Radicava is commercialized in the U.S. by Mitsubishi
Tanabe Pharma America, Inc. (MTPA).
“Seeing the potential benefit to our patients, BioScrip
registered in the MTPA National Directory as a provider for this
important therapy as soon as it was approved,” said Robert Roose,
Senior Vice President and Chief Procurement Officer at BioScrip.
“Receiving the approval as a provider of choice to dispense and
administer this limited distribution drug underscores the fact that
BioScrip is a destination of choice for our manufacturers.”
BioScrip will provide Radicava in the patient’s home or in an
infusion suite setting, depending on the patient’s care plan and
condition. These capabilities include providing the first dose of
Radicava where the patient’s care plan permits. BioScrip will
assist caregivers and patients to be independent with Radicava
therapy in the comfort of their own home, when approved by the
prescriber. Prescribers may find a list of BioScrip’s infusion
pharmacies and infusion suites by visiting the Company’s website at
www.bioscrip.com.
Radicava is administered through intravenous infusion in 28-day
cycles. Treatment usually starts with a patient receiving the
therapy for 14 consecutive days, followed by a two-week
therapy-free period. The next cycle begins with an infusion during
10 of the next 14 days, followed by another two-week treatment-free
period. The infusion of each 60mg dose takes one hour.
About BioScrip
BioScrip, Inc. is the largest independent national provider
of infusion and home care management solutions, with approximately
2,500 teammates and nearly 80 service locations across the
U.S. BioScrip partners with physicians, hospital systems,
payors, pharmaceutical manufacturers and skilled nursing facilities
to provide patients access to post-acute care
services. BioScrip operates with a commitment to bring
customer-focused pharmacy and related healthcare infusion therapy
services into the home or alternate-site setting. By collaborating
with the full spectrum of healthcare professionals and the
patient, BioScrip provides cost-effective care that is
driven by clinical excellence, customer service, and values that
promote positive outcomes and an enhanced quality of life for those
it serves.
Important Safety Information
Before you receive RADICAVA, tell your healthcare provider about
all of your medical conditions, including if you:
- are allergic to other medicines.
- are pregnant or plan to become pregnant. It is not known if
RADICAVA will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if
RADICAVA passes into your breast milk. You and your healthcare
provider should decide if you will receive RADICAVA or
breastfeed.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins,
and herbal supplements.
What are the possible side effects of RADICAVA?
- RADICAVA may cause serious side effects including
hypersensitivity (allergic) reactions and sulfite allergic
reactions.
- Hypersensitivity reactions have happened in people receiving
RADICAVA and can happen after your infusion is finished.
- RADICAVA contains sodium bisulfite, a sulfite that may cause a
type of allergic reaction that can be serious and life-threatening.
Sodium bisulfite can also cause less severe asthma episodes in
certain people. Sulfite sensitivity can happen more often in people
who have asthma than in people who do not have asthma.
- Tell your healthcare provider right away or go to the nearest
emergency room if you have any of the following symptoms: hives;
swelling of the lips, tongue, or face; fainting; breathing
problems; wheezing; trouble swallowing; dizziness; itching; or an
asthma attack (in people with asthma).
- Your healthcare provider will monitor you during treatment to
watch for signs and symptoms of all the serious side effects.
The most common side effects of RADICAVA include bruising
(contusion), problems walking (gait disturbance), and headache.
These are not all the possible side effects of RADICAVA. Call
your healthcare provider for medical advice about side effects. You
may report side effects to Mitsubishi Tanabe Pharma America, Inc.
at 1-888-292-0058 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
For more information, including full prescribing information and
patient information, please visit
www.RADICAVA.com.
Robert Roose 720-697-5179
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024